Izotropic (IZO) AI Stock Analysis

• Market Cap: C$16.27M
• Dividend Yield: N/A
• Average Volume (3M): 43.33K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.11
• Revenue Growth: N/A
• EPS Growth: 11.68%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 67,784,676
• 10 Day Avg. Volume: 24,438
• 30 Day Avg. Volume: 43,328
• PEG Ratio: -0.05
• Price to Book (P/B): -2.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -22.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.20 ▼(-27.14% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is mainly pressured by very weak financial performance (no revenue, persistent losses, negative free cash flow, and negative equity). Technical indicators also point to a bearish trend with weak momentum. Valuation provides limited offset since the company is loss-making (negative P/E) and has no dividend yield data.

Positive Factors

Niche, focused product offering

Izotropic's singular focus on a dedicated Breast CT system creates a clear product roadmap and specialization. That concentration supports deeper clinical expertise, targeted regulatory and reimbursement efforts, and a differentiated go-to-market versus general imaging vendors — durable advantages for commercialization.

Clear clinical application (3D breast imaging)

A device that delivers 3D breast imaging addresses persistent clinical needs for improved lesion localization and diagnostic accuracy. Structural trends toward higher-resolution, modality-specific imaging in breast care support long-term demand from diagnostic and screening pathways once commercial validation and reimbursement align.

Improving cash burn trend

Reported improvement in TTM free cash flow growth indicates management has begun to slow cash burn. Even though cash flow remains negative, a demonstrable reduction in burn rate is a durable operational improvement that extends runway, lowers short-term financing pressure, and increases the chance to reach commercialization milestones.

Negative Factors

No revenue and persistent losses

The absence of revenue and sustained operating losses confirm the business remains pre-commercial and reliant on investment. Over the next several months this limits ability to demonstrate product-market fit, forces continued R&D expense, and makes funding cadence and execution critical to avoid dilution or disruption.

Negative equity and small asset base

Negative shareholders' equity and a tiny asset base create elevated solvency and financing risk. This structural weakness constrains strategic flexibility, reduces leverage in partner or supplier negotiations, and increases reliance on external capital, raising the probability of dilutive financings or distressed outcomes if operational progress stalls.

Negative operating and free cash flow

Sustained negative operating and free cash flow means the company cannot self-fund development or commercialization. Even with burn-rate improvement, ongoing negative cash generation forces dependence on financing, which can delay product launches, slow market penetration, and elevate execution risk over the coming months.

Izotropic Business Overview & Revenue Model

Company Description

Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.

How the Company Makes Money

Izotropic Corporation primarily generates revenue through the sale and distribution of its breast CT imaging systems to healthcare providers, including hospitals and diagnostic centers. The company may also engage in service contracts, providing maintenance and support for its imaging systems. Additionally, Izotropic could potentially earn revenue through partnerships or collaborations with research institutions and healthcare organizations, contributing to the development and enhancement of imaging technologies. However, specific details regarding partnerships or additional revenue streams are not available.

Izotropic Financial Statement Overview

Summary

Financials are weak: TTM shows no revenue, ongoing operating and net losses, and negative gross profit. The balance sheet is strained with negative equity and meaningful debt relative to a small asset base, increasing solvency/financing risk. Cash flow remains negative (operating and free cash flow), indicating continued reliance on external funding despite some improvement in burn rate versus prior periods.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and continued operating losses (EBIT of about -2.5M and net loss of about -2.7M), indicating the business is still in a heavy investment/burn phase. While annual net losses improved versus 2022–2023 levels, losses widened again versus 2024 and gross profit remains negative, suggesting limited progress toward self-sustaining operations.

Balance Sheet

The balance sheet is strained: stockholders’ equity is negative in the most recent periods (TTM equity about -5.5M) alongside meaningful debt (TTM total debt about 3.0M). Total assets are relatively small (about 0.45M TTM), and the negative equity position implies elevated financing and solvency risk, even though debt levels have not exploded year-over-year.

Cash Flow

Cash generation remains weak with negative operating cash flow and negative free cash flow in TTM (roughly -1.0M), meaning the company is still reliant on external funding. A positive TTM free cash flow growth rate suggests the cash burn rate improved versus the prior period, but cash flow is still firmly negative and not yet showing a path to consistent funding from operations.

Breakdown	TTM	Jul 2025	Jul 2024	Jul 2023	Jul 2022	Jul 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-38.31K	-48.90K	-59.07K	-30.88K	-6.87K	-1.63K
EBITDA	-2.43M	-2.14M	-1.60M	-5.33M	-6.63M	-4.97M
Net Income	-2.75M	-3.14M	-1.56M	-5.66M	-6.67M	-4.98M
Balance Sheet
Total Assets	447.06K	414.73K	232.38K	442.11K	2.27M	4.69M
Cash, Cash Equivalents and Short-Term Investments	229.86K	274.11K	38.60K	165.69K	1.86M	4.06M
Total Debt	2.97M	2.76M	2.06M	2.14M	2.03M	0.00
Total Liabilities	5.95M	5.27M	4.08M	3.52M	2.64M	169.28K
Stockholders Equity	-5.50M	-4.86M	-3.85M	-3.07M	-374.59K	4.52M
Cash Flow
Free Cash Flow	-1.01M	-637.37K	-593.57K	-3.30M	-4.79M	-3.08M
Operating Cash Flow	-1.01M	-636.23K	-593.57K	-3.27M	-4.76M	-3.08M
Investing Cash Flow	-1.14K	-1.14K	0.00	-36.18K	-24.23K	0.00
Financing Cash Flow	1.13M	872.78K	468.18K	1.61M	2.58M	6.53M

Izotropic Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:IZO, the sentiment is Neutral. The current price of 0.28 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.26, and below the 200-day MA of 0.31, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.71 is Neutral, neither overbought nor oversold. The STOCH value of 76.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:IZO.

Izotropic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VPT	50 Neutral	C$21.55M	-5.28	―	―	28.59%	23.46%
BUX	48 Neutral	C$65.16M	-32.47	―	―	-21.89%	26.36%
EDT	45 Neutral	C$383.26M	-3.46	―	―	34.85%	-62.50%
IZO	44 Neutral	C$16.27M	-9.29	40.96%	―	―	11.68%
PINK	42 Neutral	C$40.36M	-1.50	-181.70%	―	209.29%	35.38%
SONA	41 Neutral	C$40.68M	-21.43	-2846.90%	―	―	10.97%

Izotropic Corporate Events

Izotropic Moves to Establish African and GCC Hub for Breast CT Imaging

Izotropic Corporation has signed a letter agreement with a business group to create Izotropic Africa, a Casablanca-based entity that will license, market, and distribute the IzoView Breast CT system and follow-on products across Africa and the Gulf Cooperation Council states. The move targets a rapidly growing regional market for advanced oncology imaging, where breast cancer incidence is high and mortality rates are elevated due to late diagnosis and limited access to sophisticated diagnostic tools.

Under the agreement, the business group will hold 60% of the new entity and Izotropic 40%, with both parties aiming to finalize a formal contract by April 30, 2026. The partners plan to secure a major Moroccan hospital by the first quarter of 2026 as a site for installing the first IzoView system for research, data collection, and regulatory approvals, while also evaluating local manufacturing or assembly, a strategy that could significantly extend Izotropic’s operational footprint and long-term revenue opportunities in Africa and the GCC.

The business group will lead annual business planning and engage with regional health ministries to initiate approval processes, anchoring market entry and regulatory pathways for IzoView and future products. Izotropic will provide technical, clinical, and operational support and has agreed to advance $30,000 toward an estimated first-year startup budget, with any further funding and commitments contingent on executing a formal agreement and securing financing.

The most recent analyst rating on (TSE:IZO) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.

Izotropic Raises Working Capital and Settles Debt with Equity Units

Izotropic closed a $300,000 non-brokered private placement by issuing 1.2 million units priced at $0.25, each carrying a share and three-year warrant, with proceeds earmarked for general working capital and contingent on regulatory approvals; it also plans to settle $60,000 of accrued interest on a 2022 promissory note by issuing 240,000 settlement units with identical pricing and warrant terms, pending Canadian Securities Exchange approval.

The most recent analyst rating on (TSE:IZO) stock is a Sell with a C$0.23 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.

Izotropic Plans $300,000 Private Placement to Advance IzoView Breast CT Commercialization

Izotropic Corporation has provided a corporate update outlining its strategic priority to secure capital, with an emphasis on non-dilutive financing, to fund the commercialization of its IzoView Breast CT system and accelerate additional regulatory pathways for earlier revenue generation. As it advances due diligence with potential strategic partners for global business units, territorial and manufacturing rights, distribution agreements, and expanded regulatory approvals, the company continues to run small financings to support operations. In this context, Izotropic plans to complete a non-brokered private placement of up to 1.2 million units at $0.25 per unit for gross proceeds of up to $300,000, each unit comprising one common share and one three-year warrant exercisable at $0.25, with proceeds earmarked for general working capital and subject to standard regulatory approvals and hold periods.

The most recent analyst rating on (TSE:IZO) stock is a Sell with a C$0.23 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.

Izotropic Shareholders Approve All AGM Resolutions and Lower Quorum Threshold

Izotropic Corporation reported that all resolutions presented at its Annual General and Special Meeting on December 29, 2025, were approved by shareholders, including the election of five directors for the coming year and the reappointment of its external auditor. Shareholders also passed an amendment to the company’s by-laws to reduce the quorum requirement for shareholder meetings from 20% to at least 1% of issued voting shares, a move aimed at mitigating persistent logistical challenges in distributing and returning voting materials, and which is expected to make it easier for the company to conduct formal business efficiently despite ongoing disruptions affecting investor communications.

The most recent analyst rating on (TSE:IZO) stock is a Hold with a C$0.26 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.

Izotropic Corporation Announces Debt Settlement Agreement

Izotropic Corporation has entered into a debt settlement agreement to address outstanding interest on a promissory note. The settlement involves issuing 240,000 units, each comprising a common share and a share purchase warrant, to settle $60,000 of accrued interest. This move is subject to approval by the Canadian Securities Exchange and reflects the company’s efforts to manage its financial obligations while potentially impacting its stock and market perception.

Izotropic Corporation Announces Debt Settlement Agreement

Izotropic Corporation has entered into a debt settlement agreement to address outstanding interest payable on a promissory note. The company will issue 240,000 units, each consisting of a common share and a share purchase warrant, to settle $60,000 in accrued interest. This settlement is subject to the approval of the Canadian Securities Exchange, and the securities will have a statutory hold period of four months and one day.